
 
													
 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Droxidopa
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Receives FDA Approval for Droxidopa Capsules, 100mg, 200mg, and 300mg
Details : The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Droxidopa capsules in the strengths of 100 mg, 200 mg and 300 mg, Aurobindo Pharma said in a regulatory filing.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 27, 2021
Lead Product(s) : Droxidopa
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Droxidopa
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin Receives Approval for Droxidopa Capsules
Details : Lupin has received approval for its Droxidopa Capsules, 100 mg, 200 mg, and 300 mg, from the United States Food and Drug Administration, to market a generic equivalent of Northera® Capsules, 100 mg, 200 mg, and 300 mg, of Lundbeck NA Ltd.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 19, 2021
Lead Product(s) : Droxidopa
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Droxidopa
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aurobindo Pharma Gets USFDA Nod for Generic Droxidopa Capsules
Details : The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Droxidopa capsules in the strengths of 100 mg, 200 mg and 300 mg, Aurobindo Pharma said in a regulatory filing.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 19, 2021
Lead Product(s) : Droxidopa
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Droxidopa
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Alberto Espay
Deal Size : Inapplicable
Deal Type : Inapplicable
Lundbeck TOMs Orthostatic Hypotension
Details : Droxidopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hypotension, Orthostatic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 12, 2020
Lead Product(s) : Droxidopa
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Alberto Espay
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : Droxidopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 25, 2018

Lead Product(s) : Droxidopa
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Droxidopa for Fatigue in Patients With Parkinsonism
Details : Droxidopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 27, 2018
Lead Product(s) : Droxidopa
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable

Brain Perfusion & Oxygenation in Parkinson's Disease With NOH
Details : Droxidopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 25, 2017

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Droxidopa
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Colorado Springs Neurological Associates
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Droxidopa is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 02, 2017
Lead Product(s) : Droxidopa
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Colorado Springs Neurological Associates
Deal Size : Inapplicable
Deal Type : Inapplicable

Norepinephrine-targeted Therapy for Action Control in Parkinson Disease
Details : Droxidopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 14, 2017

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Droxidopa
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Norepinephrine in Patients With Congenital Insensitivity to Pain and Anhidrosis
Details : Droxidopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hereditary Sensory and Autonomic Neuropathies.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 08, 2015
Lead Product(s) : Droxidopa
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Reset All
Reset All